aTyr Pharma
ATYR
41 hedge funds and large institutions have $61.3M invested in aTyr Pharma in 2017 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
5% more funds holding
Funds holding: 39 → 41 (+2)
0.99% less ownership
Funds ownership: 5.2% → 4.21% (-0.99%)
30% less capital invested
Capital invested by funds: $87.6M → $61.3M (-$26.3M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.34M |
| 2 |
AG
Artal Group
Luxembourg
|
+$1.1M |
| 3 |
Renaissance Technologies
New York
|
+$722K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$259K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$250K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$1.73M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$953K |
| 3 |
BlackRock
New York
|
-$682K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$455K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$220K |
ATYR Hedge Fund Activity: Q4 2017 in Review
41 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2017, worth a combined $61.3M — down 30% from $87.6M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ATYR positions and 5 closed out — a net gain of 3 holders — while 6 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $2.34M. The largest seller was Viking Global Investors, cutting an estimated $1.73M.
- 41 institutional investors held aTyr Pharma (ATYR) as of Q4 2017, up from 39 in Q3 2017.
- Funds reported $61.3M of aTyr Pharma stock for Q4 2017, down 30% quarter-over-quarter.
- 8 funds opened new aTyr Pharma positions in Q4 2017 and 5 closed out, a net change of +3 holders.
- The largest aTyr Pharma buyer in Q4 2017 was Fidelity Investments, an estimated $2.34M added.
- The largest aTyr Pharma seller in Q4 2017 was Viking Global Investors, an estimated $1.73M sold.
Based on aggregated 13F filings for Q4 2017.